Author:
Selmani Zohair,Molimard Chloé,Overs Alexis,Bazan Fernando,Chaigneau Loic,Dobi Erion,Meneveau Nathalie,Mansi Laura,Paillard Marie-Justine,Meynard Guillaume,Viot Julien,Algros Marie-Paule,Borg Christophe,Feugeas Jean-Paul,Pivot Xavier,Prétet Jean-Luc,Curtit Elsa
Abstract
AbstractBreast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expression of 21 specific genes from tumor tissue, including Ki67. The primary aim of this study was to assess the agreement between Ki67RNA obtained with Oncotype DX RS and Ki67IHC. Other objectives were to analyze the association between the event free survival (EFS) and the expression level of Ki67RNA; and association between RS and Ki67RNA. Herein, we report a low agreement of 0.288 by Pearson correlation coefficient test between Ki67IHC and Ki67RNA in a cohort of 98 patients with early ER+/HER2− breast cancers. Moreover, Ki67RNAhigh tumors were significantly associated with the occurrence of events (p = 0.03). On the other hand, we did not find any association between Ki67IHC and EFS (p = 0.26). We observed a low agreement between expression level of Ki67RNA and Ki67 protein labelling by IHC. Unlike Ki67IHC and independently of the RS, Ki67RNA could have a prognostic value. It would be interesting to better assess the prognosis and predictive value of Ki67RNA measured by qRT-PCR. The Ki67RNA in medical routine could be a good support in countries where Oncotype DX is not accessible.
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 70, 313–313 (2020).
2. Curigliano, G. et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 28, 1700–1712 (2017).
3. Gluz, O. et al. Prospective WSG phase III Plan B trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. Eur. J. Cancer 57, S6 (2016).
4. Curtit, E., Mansi, L., Maisonnette-Escot, Y., Sautière, J.-L. & Pivot, X. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 43, 921–930 (2017).
5. Pivot, X. et al. In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?. Oncologist 20, 344–350 (2015).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献